Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Cardiometabolic health
Advertisement
Pfizer Expands Obesity Pipeline with $4.9B Metsera Acquisition
NEW YORK, September 22, 2025 – In a landmark move shaping the future of obesity and cardiometabolic disease treatments,...
Lilly’s Oral GLP-1 Outperforms Oral Semaglutide in Phase 3 Trial
INDIANAPOLIS, Sept. 17, 2025 – Eli Lilly and Company (NYSE: LLY) announced today that its investigational oral GLP-1 receptor...
Advertisement
